You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
口罩、疫苗、檢測等板塊集體走強!疫情反彈下抗疫題材“捲土重來”
格隆匯 06-17 11:28

源於北京新發地疫情爆發的影響,今日口罩、疫苗等相關概念股漲嗨了。

截至發稿,口罩板塊中,鹿港文化衝擊漲停,南衞股份漲超8%,海王生物漲超6%,雷賽智能、奧美醫療、泰達股份、英科醫療均漲超4%,尚榮醫療、道恩股份等概念股皆大幅跟漲。

(行情來源:同花順)

而疫苗概念股亦有所活躍。截至發稿,神奇製藥、現代製藥迅速漲停,華蘭生物、達安基因、海王生物皆漲超6%,魯抗醫藥、海正醫藥、未名醫藥等股則隨之走強。

(行情來源:同花順)

除此之外,新冠肺炎檢測板塊也集體走強。截止發稿,安科生物漲超8%,達安基因漲超7%,熱景生物漲超6%,碩世生物、華大基因、邁克生物等股紛紛跟漲。

(行情來源:同花順)

結合當下新冠疫情的具體情況來看,此輪抗疫題材走強主要是受北京疫情加劇之下,應急響應級別由三級提升到二級這一相關消息刺激的。

6月13日,北京新增報告本地確診病例36例,累計報告本地確診病例463例;6月14日,北京新增報告本地確診病例36例,累計報告本地確診病例499例;6月15日,北京新增報告本地確診病例27例,累計報告本地確診病例526例;而截至6月16日,北京新增報告本地確診病例31例,累計報告本地確診病例557例。

北京本土四日新增130例,這一數據無不向外界傳達了一個信號——北京受疫情的影響程度,恐怕要比外界想象中的更加嚴峻。

在此背景之下,北京應急響應級別連夜由三級提升到二級。6月16日晚,北京市政府副祕書長陳蓓在會上通報,近日在國家衞生健康委專家組的指導下進行分析,經北京市新冠肺炎防控工作領導小組研究決定,自6月16日即時起北京市應急響應級別由三級調至二級。

其中,在核酸檢測方面,北京強力擴大核酸檢測範圍。據北京市政府副祕書長陳蓓,境外入京人員全部集中觀察核酸檢測,中高風險街鄉、新發地市場相關人員禁止出京。其他人員堅持非必要不出京,確需離京的,要持7日內核酸檢測陰性證明。在十類人員核酸檢測應檢盡檢的基礎上,對過去14天內到過新發地、玉泉東、天陶紅蓮市場等重點區域人員及密接者落實檢測全覆蓋,並根據需要擴大檢測範圍。

在口罩等防護用品的佩戴上,北京市政府副祕書長陳蓓表示,農貿市場、菜市場、餐飲店、單位食堂等場所相關從業人員必須佩戴口罩和手套。醫療衞生等專業機構、從事公共服務人員等必須佩戴口罩。小於1米近距離接觸、處於人員密集、封閉擁擠場所,必須佩戴口罩。此外,北京市教委發佈7條校園“新規”表示:學生上課全程必須佩戴戴口罩。

值得注意的是,上述防疫措施的升級也使得口罩、消毒液等防疫物品銷量大幅飆升。

6月14日,阿里健康大藥房口罩購買量環比增加5倍。同日百度搜索大數據顯示,口罩再次成為大家關注的重點,“醫用口罩品牌”搜索熱度也在近24個小時內飆升20倍。此外,拼多多數據顯示,6月12日至14日三天平台口罩和消毒液的銷量同比上月銷售增長200%,環比上週增長400%;而蘇寧易購數據顯示,6月13日-14日,蘇寧超市口罩銷量暴增300.5%。

對此,長城證券表示,短期來看,疫情的反覆有望持續加深市場投資者對醫藥板塊的青睞,建議重點關注檢測、疫苗、防護等細分領域;長期來看,政策不斷推動重大疫情防控體系建設,疫情的反覆或將加快財政投入力度,利好醫藥行業的長期穩健發展。

此外,新時代證券也表示,疫情有所反覆,建議關注受益的口罩機、注塑機產業:國內外疫情反覆背景下,預計有所放鬆的防疫要求將再次提高,如口罩佩戴、核酸檢測、温度測量等,對應的防疫用品需求將再次提高,包括口罩、額温槍等。另外國內外疫情反覆,居民對食品及生活用品進行囤貨,冰箱冰櫃等家電需求持續旺盛。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account